Brexanolone

SAGE Therapeutics Inc (SAGE) Attains 52-Week High on Encouraging Clinical Results; Needham Cheers

Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.

Jason Cohen — November 9, 2017, 3:43 PM EDT